Cancer Precision Medicine: Implications for Stakeholders
Breakthroughs in data science and biology are helping providers and companies tailor cancer treatment more precisely, with important implications for investors, executives, and patients. Speakers are leaders in clinical diagnostics, healthcare systems, medicine, reimbursement, and therapeutic evidence generation.
• How big data currently available on patients, physicians and payers helps improve efficacy and efficiency of oncology care delivery
• Genomic discoveries that are creating opportunities to develop more personalized cancer treatment pathways for patients
• Precision medicine is creating new revenue opportunities for pharmaceutical companies and payers
• Updates from ASCO 2019
• Opportunities for investors and entrepreneurs to solve gaps in precision medicine delivery
James Crawford, MD, PhD (Moderator)
Ghassan Abou-Alfa, MD, CBS '16 (MSKCC GI Oncology)
Mike Kolodjiez, MD (Chief Innovation Officer, ADVI and National Medical Director, Oncology, Aetna)
Melisa Tucker (VP, Product Development, Flatiron Health)
Burt Zweigenhalt (Managing Partner, Upstream Partners)
Date: June 5, 2019
Time: 6:00-8:30 PM (Panel discussion begins at 6:30 and will be followed by informal networking and refreshments at about 8:00)
Location: Manatt Health, 7 Times Square (bet. 41st-42nd Sts.,) 5th Floor, NYC
Tickets: $35 members; $45 non-members; $60 at the door
SPECIAL OFFER: Columbia Business School Alumni Club of New York offers ONE FREE EVENT for new members who sign up for the first time ($85 or more). Click here to join now and then contact us to receive your promotional code before you register for the event of your choice (sports events, holiday parties and mixers are excluded.)
James Crawford, MD, PhD, SVP of Laboratory Services, Northwell Health System & Chair of the Department of Pathology & Laboratory Medicine, Zucker School of Medicine at Hofstra/Northwell (moderator). Jim is a leading proponent of the role of pathology and the clinical laboratory in patient-centered care and in accountable care. He is founding member and chair of the board of directors for the Project Santa Fe Foundation, which is advancing the concept of Clinical Laboratory 2.0 for developing the evidence base for the value statements of laboratory services in the next era of American health care, including Precision Medicine. He has authored over 260 peer-review papers, critical reviews, and book chapters, and was the senior editor of three books. He received his MD and PhD from Duke University School of Medicine and did post-graduate training in GI pathology and anatomic pathology at Brigham & Women's Hospital.
Ghasson Abou-Alfa, MD, Professor of Medicine at Weill Cornell Medicine and attending physician at Memorial Sloan Kettering Cancer Center (MSKCC), specializes in the treatment of gastrointestinal malignancies. He is the Chair of the National Cancer Institute (NCI) Hepatobiliary Task Force and a member of the NCI AIDS Malignancy Consortium Steering Committee. Ghasson has led major national and international clinical trials for a number of leading targeted therapies for GI cancers. Most recently, he led a clinical trial for cabozantinib (Exelexis/ Ipsen), which the FDA approved for the heptocellular carcinoma indication in January 2019. He now focuses on determining the right CAR-T antigens for HCC and analyzing world wide data to help analyze the genetic profile of patients with HCC and help determine the appropriate targeted therapy that will be most valuable. He completed his residency and fellowship at Yale University, and later joined the Yale faculty. He received his MBA from Columbia University in 2016. Ghasson is the President-Elect of the International Society of Gastrointestinal Oncology.
Mike Kolodziej, MD, is VP and chief innovation officer of ADVI Health Inc., where he focuses on supporting innovative alternative payment programs for oncology on behalf of life-science, payer and provider organizations. Previously, he worked at Flatiron and served as National Medical Director for Oncology Strategies at Aetna, where he built the insurer's first oncology medical home and pioneered projects in personalized medicine and value-based reimbursement models. He is board certified in internal medicine, hematology and medical oncology and received his MD from Washington University School of Medicine in St. Louis.
Melisa Tucker is Vice President of Product Management and Operations at Flatiron Health, a health tech company in New York that Roche bought last year for $1.9B. Flatiron aims to accelerate research by learning from the experience of every cancer patient. Prior to Flatiron, Melisa worked in healthcare consulting at McKinsey & Company and in early-stage venture capital. She holds an A.B. in Chemistry from Princeton University and an MBA from Harvard Business School.
Burt Zweigenhaft is a key industry thought leader and accomplished entrepreneur/ executive in the specialty biotech pharmaceutical and oncology cancer care ecosystems. He is the Managing Partner of Upstream-Partners, LLC, a NY-based investment advisory company focused on incubating to commercialization new healthcare delivery services, specialty bio-pharmaceuticals, genomics, precision medicine, and artificial intelligence technologies into healthcare ecosystems. He also serves as senior advisor to the shareholder group of Cancer Treatment Centers of America (CTCA).
Many thanks to Manatt Health for sponsoring this program. This event was organized by Johnson Qian (CBS '18) and fellow members of the Columbia Business School Alumni Club of NY Healthcare Committee, Brad Pickar, Wendy Diller and Deepak Mittal.